Science

2024

  • . Phase 1/2 Trial of Oral EPI-7386 (masofaniten) in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Phase 1 results and Phase 2 design.

    Poster ASCO GU 2024

2023

  • . Phase 1/2 Trial of Oral EPI-7386 (masofaniten) in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Current Phase 1 (P1) results.

    PCF 2023 Poster Presentation
  • . Phase 1/2 Trial of Oral EPI-7386 (masofaniten) in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Current Phase 1 (P1) results. ESMO Virtual Congress 2023.

    ESMO 2023 Poster Presentation
  • Lacetti, Andrew et al. Phase 1/2 Trial of Oral EPI-7386 in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Preliminary Results from the Phase 1 (P1) Dose-optimization Component of the Study. 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium.

    ASCO GU 2023 Poster Presentation
  • Pachynski, Russel et al. A Phase 1 Trial of Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Update From the First-in-Human Study. 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.

    ASCO GU 2023 Poster Presentation